

Ricolinostat

Catalog No: tcsc0965



Available Sizes

Size: 5mg

Size: 10mg

Size: 50mg

Size: 100mg



Specifications

CAS No:

1316214-52-4

Formula:

$C_{24}H_{27}N_5O_3$

Pathway:

Epigenetics;Cell Cycle/DNA Damage

Target:

HDAC;HDAC

Purity / Grade:

>98%

Solubility:

DMSO : \geq 50 mg/mL (115.34 mM)

Alternative Names:

ACY-1215;Rocilinostat

Observed Molecular Weight:

433.5


Product Description

Ricolinostat (ACY-1215) is a potent and selective **HDAC6** inhibitor, with an **IC₅₀** of 5 nM. ACY-1215 also inhibits **HDAC1**, **HDAC2**, and **HDAC3** with **IC₅₀**s of 58, 48, and 51 nM, respectively.

IC50 & Target: IC50: 5 nM (HDAC6), 58 nM (HDAC1), 48 nM (HDAC2), 51 nM (HDAC3)^[1]

In Vitro: Ricolinostat (ACY-1215) has slight activity against HDAC8 (IC₅₀=0.1 μM), and has minimal activity (IC₅₀>1 μM) against HDAC4, HDAC5, HDAC7, HDAC9, HDAC11, Sirtuin1, and Sirtuin2. The effect of Ricolinostat (ACY-1215) on multiple myeloma (MM) cell viability is determined with MTT assays using MM cell lines. Exposure of MM cell lines for 48 hours results in dose-dependent decreased viability, with IC₅₀ values ranging from 2-8μM. Ricolinostat (ACY-1215) demonstrates significant activity in the MM Bortezomib-resistant cell line (ANBL-6.BR), demonstrating the ability of Ricolinostat (ACY-1215) to overcome Bortezomib resistance^[1].

In Vivo: Mice treated with Ricolinostat (ACY-1215), Bortezomib, or Ricolinostat plus Bortezomib show a significant delay in tumor growth (P=0.01, P=0.006, and P[1].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!